Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
80 hedge funds and large institutions have $67M invested in Adaptimmune Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 14 closing their positions.
167% more call options, than puts
Call options by funds: $24K | Put options by funds: $9K
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
10% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 21
1% less funds holding
Funds holding: 81 → 80 (-1)
1.78% less ownership
Funds ownership: 9.89% → 8.1% (-1.8%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less capital invested
Capital invested by funds: $144M → $67M (-$77.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$10.8M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$5.24M |
| 3 |
Renaissance Technologies
New York
|
+$634K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$372K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$35.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$3.74M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.61M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.31M |
| 5 |
Millennium Management
New York
|
-$500K |
ADAP Hedge Fund Activity: Q4 2024 in Review
80 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2024, worth a combined $67M — down 54% from $144M a quarter earlier.
Fund positioning in ADAP was balanced in Q4 2024: 14 funds opened new positions, 14 closed out, 19 added to existing stakes and 21 trimmed.
The largest buyer was Two Seas Capital, opening a new position worth an estimated $10.8M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $35.8M sold.
- 80 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2024, down from 81 in Q3 2024.
- Funds reported $67M of Adaptimmune Therapeutics stock for Q4 2024, down 54% quarter-over-quarter.
- 14 funds opened new Adaptimmune Therapeutics positions in Q4 2024 and 14 closed out, a net change of 0 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2024 was Two Seas Capital, an estimated $10.8M added.
- The largest Adaptimmune Therapeutics seller in Q4 2024 was Matrix Capital Management Company, an estimated $35.8M sold.
Based on aggregated 13F filings for Q4 2024.